We are live on
!
Find out more
FLSM
Frazier Life Sciences Management Portfolio holdings
AUM
$4.59B
1-Year Est. Return
237.58%
This Fund
S&P 500
This Quarter
Est. Return
+34.04%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.89B
AUM Growth
+$163M
(+4.4%)
Cap. Flow
+$27.4M
Cap. Flow
% of AUM
0.71%
Top 10 Holdings %
Top 10 Hldgs %
73.49%
Holding
43
New
3
Increased
8
Reduced
10
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mirum Pharmaceuticals
MIRM
|
+$83.2M |
| 2 |
BioCryst Pharmaceuticals
BCRX
|
+$31.1M |
| 3 |
Erasca
ERAS
|
+$23M |
| 4 |
Monte Rosa Therapeutics
GLUE
|
+$19.1M |
| 5 |
PVLA
Palvella Therapeutics
PVLA
|
+$16.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RNAM
Avidity Biosciences
RNAM
|
+$70.9M |
| 2 |
ABVX
Abivax
ABVX
|
+$51M |
| 3 |
RAPT
RAPT Therapeutics
RAPT
|
+$33.3M |
| 4 |
Revolution Medicines
RVMD
|
+$12.3M |
| 5 |
Travere Therapeutics
TVTX
|
+$9.23M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Lexeo Therapeutics
LXEO
$421M
| $25.4M | 0.65% |
4,424,725
| – | – |
|
27
Alkermes
ALKS
$8.26B
| $24.8M | 0.64% |
700,647
| – | – |
|
28
Aclaris Therapeutics
ACRS
$963M
| $18.5M | 0.48% |
+4,925,374
| New | +$16.6M |
|
|
29
Monte Rosa Therapeutics
GLUE
$1.24B
| $16.4M | 0.42% |
+1,000,000
| New | +$19.1M |
|
30
Immunocore
IMCR
$1.93B
| $14.6M | 0.38% |
484,782
+100,000
| +26% | +$3.24M |
|
31
MannKind Corp
MNKD
$1.34B
| $14.5M | 0.37% |
5,900,000
+1,675,000
| +40% | +$7.47M |
|
|
VALN
32
Valneva
VALN
$643M
| $14.3M | 0.37% |
2,291,666
| – | – |
|
33
Evolus
EOLS
$592M
| $10.8M | 0.28% |
2,630,665
| – | – |
|
34
NewAmsterdam Pharma Warrant
NAMSW
| $10M | 0.26% |
500,333
| – | – |
|
35
Allogene Therapeutics
ALLO
$750M
| $9.26M | 0.24% |
3,796,668
-72,082
| -2% | -$144K |
|
|
AUTL
36
Autolus Therapeutics
AUTL
$649M
| $6.14M | 0.16% |
4,447,910
-175,414
| -4% | -$266K |
|
37
iBio
IBIO
$73M
| $3.71M | 0.1% |
1,953,467
| – | – |
|
38
Xilio Therapeutics
XLO
$59.7M
| $3.55M | 0.09% |
422,505
-2
| -0% | -$16 |
|
|
ABVX
39
Abivax
ABVX
$10.3B
| – | – |
-378,300
| Closed | -$51M |
|
40
Design Therapeutics
DSGN
$981M
| – | – |
-521,000
| Closed | -$4.89M |
|
|
RAPT
41
DELISTED
RAPT Therapeutics
RAPT
| – | – |
-983,333
| Closed | -$33.3M |
|
|
RNAM
42
DELISTED
Avidity Biosciences
RNAM
| – | – |
-983,125
| Closed | -$70.9M |
|
|
43
Travere Therapeutics
TVTX
$6.32B
| – | – |
-241,592
| Closed | -$9.23M |
|
Similar funds
AF
BWA
CCA
AT
SLG
TYCC
LP
CSP
Frazier Life Sciences Management's Q1 2026 Portfolio in Review
As of Q1 2026, Frazier Life Sciences Management held 43 positions worth $3.89B, up 4.4% from $3.72B the previous quarter. Its ten largest holdings account for 73% of the portfolio.
Frazier Life Sciences Management's Q1 2026 filing shows 3 new, 8 increased, 10 reduced and 5 closed positions. Its largest new stake was BioCryst Pharmaceuticals: 4,009,240 shares worth $38.2M. The largest sale was Avidity Biosciences, an estimated $70.9M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.
- Frazier Life Sciences Management's largest Q1 2026 buy was BioCryst Pharmaceuticals: 4,009,240 shares worth $38.2M.
- Frazier Life Sciences Management added most to Mirum Pharmaceuticals in Q1 2026, an estimated $83.2M increase.
- Frazier Life Sciences Management's biggest Q1 2026 reduction was Revolution Medicines, cutting an estimated $12.3M.
- Frazier Life Sciences Management fully exited Avidity Biosciences in Q1 2026, selling an estimated $70.9M.
- Frazier Life Sciences Management's ten largest holdings make up 73% of its $3.89B portfolio in Q1 2026.
- Frazier Life Sciences Management opened 3 new positions and closed 5 in Q1 2026.
- Frazier Life Sciences Management's portfolio value rose 4.4% quarter-over-quarter to $3.89B.
Based on Frazier Life Sciences Management's 13F filing for Q1 2026, filed 15 May 2026.